P/E ratio for Oncolytics Biotech (ONCY)
P/E ratio as of May 2024 (TTM): -3.53
According to Oncolytics Biotech 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.53395. At the end of 2022 the company had a P/E ratio of -4.86.
P/E ratio history for Oncolytics Biotech from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.86 | 35.77% |
| 2021 | -3.58 | -38.4% |
| 2020 | -5.81 | 41.3% |
| 2019 | -4.11 | 83.41% |
| 2018 | -2.24 | -63.77% |
| 2017 | -6.19 | 182.59% |
| 2016 | -2.19 | -25.15% |
| 2015 | -2.93 | -0.36% |
| 2014 | -2.94 | -48.96% |
| 2013 | -5.75 | -30.91% |
| 2012 | -8.33 | -12.74% |
| 2011 | -9.54 | -45.57% |
| 2010 | -17.5 | 95.25% |
| 2009 | -8.98 | 189.4% |
| 2008 | -3.10 | 3.4% |
| 2007 | -3.00 | -141.67% |
| 2006 | 7.20 | -54.82% |
| 2005 | 15.9 | -208.6% |
| 2004 | -14.7 | -193.28% |
| 2003 | 15.7 | 86.34% |
| 2002 | 8.44 | -67.3% |
| 2001 | 25.8 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Eli Lilly LLY | 141 | -4,095.87% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.1 | -412.90% | 🇺🇸 USA |
 Mirati Therapeutics MRTX | -4.58 | 29.57% | 🇺🇸 USA |
 Aeterna Zentaris AEZS | -1.71 | -51.48% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -7.03 | 98.93% | 🇮🇱 Israel |
 AVEO Oncology
AVEO | -17.9 | 405.30% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.